<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34437579</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>14</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>8</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Persisting symptoms three to eight months after non-hospitalized COVID-19, a prospective cohort study.</ArticleTitle><Pagination><StartPage>e0256142</StartPage><MedlinePgn>e0256142</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0256142</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0256142</ELocationID><Abstract><AbstractText>Long-COVID-19 is a proposed syndrome negatively affecting the health of COVID-19 patients. We present data on self-rated health three to eight months after laboratory confirmed COVID-19 disease compared to a control group of SARS-CoV-2 negative patients. We followed a cohort of 8786 non-hospitalized patients who were invited after SARS-CoV-2 testing between February 1 and April 15, 2020 (794 positive, 7229 negative). Participants answered online surveys at baseline and follow-up including questions on demographics, symptoms, risk factors for SARS-CoV-2, and self-rated health compared to one year ago. Determinants for a worsening of self-rated health as compared to one year ago among the SARS-CoV-2 positive group were analyzed using multivariate logistic regression and also compared to the population norm. The follow-up questionnaire was completed by 85% of the SARS-CoV-2 positive and 75% of the SARS-CoV-2 negative participants on average 132 days after the SARS-CoV-2 test. At follow-up, 36% of the SARS-CoV-2 positive participants rated their health "somewhat" or "much" worse than one year ago. In contrast, 18% of the SARS-CoV-2 negative participants reported a similar deterioration of health while the population norm is 12%. Sore throat and cough were more frequently reported by the control group at follow-up. Neither gender nor follow-up time was associated with the multivariate odds of worsening of self-reported health compared to one year ago. Age had an inverted-U formed association with a worsening of health while being fit and being a health professional were associated with lower multivariate odds. A significant proportion of non-hospitalized COVID-19 patients, regardless of age, have not returned to their usual health three to eight months after infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>S&#xf8;raas</LastName><ForeName>Arne</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1622-591X</Identifier><AffiliationInfo><Affiliation>Department of Microbiology, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalleberg</LastName><ForeName>Karl Trygve</ForeName><Initials>KT</Initials><Identifier Source="ORCID">0000-0003-4968-2295</Identifier><AffiliationInfo><Affiliation>Age Labs AS, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dahl</LastName><ForeName>John Arne</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xf8;raas</LastName><ForeName>Camilla Lund</ForeName><Initials>CL</Initials><Identifier Source="ORCID">0000-0002-3964-4351</Identifier><AffiliationInfo><Affiliation>Department of Environmental and Occupational Medicine, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Myklebust</LastName><ForeName>Tor &#xc5;ge</ForeName><Initials>T&#xc5;</Initials><AffiliationInfo><Affiliation>Department of Research and Innovation, M&#xf8;re and Romsdal Hospital Trust, &#xc5;lesund, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Registry of Norway, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Axelsen</LastName><ForeName>Eyvind</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-5244-2511</Identifier><AffiliationInfo><Affiliation>F&#xfc;rst Medical Laboratory, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lind</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8289-8410</Identifier><AffiliationInfo><Affiliation>Department of Microbiology, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xe6;vre-Jensen</LastName><ForeName>Roar</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-5972-7181</Identifier><AffiliationInfo><Affiliation>Department of Medical Microbiology, Vestre Viken Hospital Trust, Drammen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>J&#xf8;rgensen</LastName><ForeName>Silje Bakken</ForeName><Initials>SB</Initials><Identifier Source="ORCID">0000-0002-3135-1431</Identifier><AffiliationInfo><Affiliation>Department of Clinical Microbiology and Infection Control, Akershus University Hospital, L&#xf8;renskog, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Istre</LastName><ForeName>Mette S</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0001-5674-3522</Identifier><AffiliationInfo><Affiliation>Department of Microbiology, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kjetland</LastName><ForeName>Eyrun F</ForeName><Initials>EF</Initials><Identifier Source="ORCID">0000-0002-5552-1095</Identifier><AffiliationInfo><Affiliation>Department of Microbiology, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nelson R Mandela School of Medicine, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ursin</LastName><ForeName>Giske</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cancer Registry of Norway, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dept of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dept. of Preventive Medicine, University of Southern California, Los Angeles, California, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005334" MajorTopicYN="N">Fever</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060888" MajorTopicYN="N">Real-Time Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057566" MajorTopicYN="N">Self Report</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Dr S&#xf8;raas reported being an employee and shareholder at Age Labs outside of the submitted work. Dr Kalleberg reported receiving grants from the Norwegian Research Council during the conduct of the study and being a shareholder at Age Labs outside of the submitted work. This does not alter our adherence to PLOS ONE policies on sharing data and materials.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>26</Day><Hour>17</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>8</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34437579</ArticleId><ArticleId IdType="pmc">PMC8389372</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0256142</ArticleId><ArticleId IdType="pii">PONE-D-21-09363</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F, Group ftGAC-P-ACS. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020;324(6):603&#x2013;5. doi: 10.1001/jama.2020.12603</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, et al.. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. The Lancet Psychiatry. 2020. doi: 10.1016/S2215-0366(20)30203-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(20)30203-0</ArticleId><ArticleId IdType="pmc">PMC7234781</ArticleId><ArticleId IdType="pubmed">32437679</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde MW, Kim SS, Lindsell CJ, Rose EB, Shapiro NI, Files DC, et al.. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network&#x2014;United States, March&#x2013;June 2020. Morbidity and Mortality Weekly Report. 2020;69(30):993. doi: 10.15585/mmwr.mm6930e1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6930e1</ArticleId><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Troyer EA, Kohn JN, Hong S. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. Brain, behavior, and immunity. 2020. doi: 10.1016/j.bbi.2020.04.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.04.027</ArticleId><ArticleId IdType="pmc">PMC7152874</ArticleId><ArticleId IdType="pubmed">32298803</ArticleId></ArticleIdList></Reference><Reference><Citation>Stavem K, Ghanima W, Olsen MK, Gilboe HM, Einvik G. Prevalence and Determinants of Fatigue after COVID-19 in Non-Hospitalized Subjects: A Population-Based Study. International Journal of Environmental Research and Public Health. 2021;18(4):2030. doi: 10.3390/ijerph18042030</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph18042030</ArticleId><ArticleId IdType="pmc">PMC7921928</ArticleId><ArticleId IdType="pubmed">33669714</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg B, Mohn KG-I, Brokstad KA, Zhou F, Linchausen DW, Hansen B-A, et al.. Long COVID in a prospective cohort of home-isolated patients. Nature Medicine. 2021. doi: 10.1038/s41591-021-01433-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01433-3</ArticleId><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al.. Post-acute COVID-19 syndrome. Nature Medicine. 2021;27(4):601&#x2013;15. doi: 10.1038/s41591-021-01283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Libby P, L&#xfc;scher T. COVID-19 is, in the end, an endothelial disease. European heart journal. 2020;41(32):3038&#x2013;44. Epub 2020/09/04. doi: 10.1093/eurheartj/ehaa623 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa623</ArticleId><ArticleId IdType="pmc">PMC7470753</ArticleId><ArticleId IdType="pubmed">32882706</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang AC, Kern F, Losada PM, Agam MR, Maat CA, Schmartz GP, et al.. Dysregulation of brain and choroid plexus cell types in severe COVID-19. Nature. 2021. doi: 10.1038/s41586-021-03710-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03710-0</ArticleId><ArticleId IdType="pmc">PMC8400927</ArticleId><ArticleId IdType="pubmed">34153974</ArticleId></ArticleIdList></Reference><Reference><Citation>Sollini M, Ciccarelli M, Cecconi M, Aghemo A, Morelli P, Gelardi F, et al.. Vasculitis changes in COVID-19 survivors with persistent symptoms: an [18F]FDG-PET/CT study. European Journal of Nuclear Medicine and Molecular Imaging. 2021;48(5):1460&#x2013;6. doi: 10.1007/s00259-020-05084-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-020-05084-3</ArticleId><ArticleId IdType="pmc">PMC7595761</ArticleId><ArticleId IdType="pubmed">33123760</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg P, Arora U, Kumar A, Wig N. The &#x201c;post-COVID&#x201d; syndrome: How deep is the damage? Journal of Medical Virology. 2021;93(2):673&#x2013;4. doi: 10.1002/jmv.26465</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26465</ArticleId><ArticleId IdType="pmc">PMC7461449</ArticleId><ArticleId IdType="pubmed">32852801</ArticleId></ArticleIdList></Reference><Reference><Citation>Kjetland EF, Kalleberg KT, S&#xf8;raas CL, Hammarstr&#xf6;m B, Myklebust T&#xc5;, Jenum S, et al.. Risk factors for community transmission of SARS-CoV-2. A cross-sectional study in 116,678 people. medRxiv. 2020:2020.12.23.20248514. doi: 10.1101/2020.12.23.20248514</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.12.23.20248514</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose AJ, Sacks NC, Deshpande AP, Griffin SY, Cabral HJ, Kazis LE. Single-change items did not measure change in quality of life. Journal of clinical epidemiology. 2008;61(6):603&#x2013;8. Epub 2008/05/13. doi: 10.1016/j.jclinepi.2007.07.010 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2007.07.010</ArticleId><ArticleId IdType="pubmed">18471664</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer T, Richter S, Raspe H. Agreement between pre-post measures of change and transition ratings as well as then-tests. BMC Medical Research Methodology. 2013;13(1):52. doi: 10.1186/1471-2288-13-52</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-13-52</ArticleId><ArticleId IdType="pmc">PMC3626663</ArticleId><ArticleId IdType="pubmed">23537286</ArticleId></ArticleIdList></Reference><Reference><Citation>Garratt AM, Stavem K. Measurement properties and normative data for the Norwegian SF-36: results from a general population survey. Health and quality of life outcomes. 2017;15(1):51. Epub 2017/03/16. doi: 10.1186/s12955-017-0625-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12955-017-0625-9</ArticleId><ArticleId IdType="pmc">PMC5351285</ArticleId><ArticleId IdType="pubmed">28292292</ArticleId></ArticleIdList></Reference><Reference><Citation>Bliddal S, Banasik K, Pedersen OB, Nissen I, Cantwell L, Schwinn M, et al.. Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients. medRxiv. 2021:2021.01.22.21249945. doi: 10.1038/s41598-021-92045-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-92045-x</ArticleId><ArticleId IdType="pmc">PMC8222239</ArticleId><ArticleId IdType="pubmed">34162913</ArticleId></ArticleIdList></Reference><Reference><Citation>Munblit D, Bobkova P, Spiridonova E, Shikhaleva A, Gamirova A, Blyuss O, et al.. Risk factors for long-term consequences of COVID-19 in hospitalised adults in Moscow using the ISARIC Global follow-up protocol: StopCOVID cohort study. medRxiv. 2021:2021.02.17.21251895. doi: 10.1101/2021.02.17.21251895</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.02.17.21251895</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JS, Kim SY, Kim TS, Hong KH, Ryoo NH, Lee J, et al.. Evidence of Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection After Recovery from Mild Coronavirus Disease 2019. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2020. Epub 2020/11/22. doi: 10.1093/cid/ciaa1421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1421</ArticleId><ArticleId IdType="pmc">PMC7890673</ArticleId><ArticleId IdType="pubmed">33219681</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>